Who is the manufacturer of Glasdegib?

Glasdegib trade nameDaurismo is jointly developed and produced by American pharmaceutical companies Pfizer and Hikma Pharmaceuticals. This drug is an inhibitor of the Hedgehog signaling pathway. It is mainly used to treat patients with acute myeloid leukemia (AML). Especially when used in combination with the chemotherapy drug azacitidine, it can significantly improve the survival of patients.

The Hedgehog signaling pathway plays an important role in the development of various cancers, including leukemia and tumor proliferation caused by genetic mutations. Glassgib exerts anti-tumor effects by inhibiting this signaling pathway, preventing the proliferation and survival of cancer cells. In clinical applications, Glasgib is often used to treat AML patients who are old and frail and cannot tolerate standard chemotherapy.

Glass Gibb is produced in cooperation with the two companies mentioned above and is licensed and produced worldwide. Glassgib was first approved by the U.S. Food and Drug Administration (FDA) in 2018 for the treatment of acute myeloid leukemia in combination with azacitidine, particularly in patients who cannot receive chemotherapy. The production and sales of drugs may vary according to the needs of different countries and regions, and are mainly led by Pfizer, while Hikma Pharmaceuticals is responsible for production and supply in some regions.

The production quality control of this drug is very strict and follows the highest standards of global drug production to ensure the safety, effectiveness and stability of the drug. Whether in the initial research and development stage or in the production process after the drug is launched, Chevron and Genk strictly abide by international drug production regulations to ensure that each batch of Glassgib's drugs can meet the needs of clinical treatment.

Reference materials:https://en.wikipedia.org/wiki/Glasdegib